EDSA Edesa Biotech, Inc. Stock Quote

EDSA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.03	Insider Own	28.83%	Shs Outstand	13.25M	Perf Week	-18.20%
Market Cap	75.92M	Forward P/E	-	EPS next Y	-0.79	Insider Trans	0.00%	Shs Float	9.47M	Perf Month	-37.72%
Income	-11.70M	PEG	-	EPS next Q	-0.34	Inst Own	16.40%	Short Float	3.81%	Perf Quarter	-7.76%
Sales	0.00M	P/S	151833.00	EPS this Y	-34.10%	Inst Trans	5.68%	Short Ratio	0.11	Perf Half Y	-6.96%
Book/sh	1.19	P/B	4.50	EPS next Y	-13.70%	ROA	-75.40%	Target Price	19.00	Perf Year	7.00%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-94.10%	52W Range	4.05 - 12.00	Perf YTD	25.88%
Dividend	-	P/FCF	-	EPS past 5Y	21.60%	ROI	-97.00%	52W High	-56.17%	Beta	0.60
Dividend %	-	Quick Ratio	14.60	Sales past 5Y	-15.40%	Gross Margin	-	52W Low	29.72%	ATR	0.39
Employees	12	Current Ratio	14.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	24.98	Volatility	7.40% 5.85%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-80.20%	Profit Margin	-	Rel Volume	0.05	Prev Close	5.35
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	3.34M	Price	5.26
Recom	-	SMA20	-20.79%	SMA50	-28.49%	SMA200	-12.74%	Volume	84,060	Change	-1.68%

Dec-01-21 07:58AM	Edesa Biotech Marks Enrollment Milestone in Dermatitis Study ACCESSWIRE -9.34%
Nov-04-21 08:00AM	Edesa Biotech Extends COVID-19 Clinical Study to Poland ACCESSWIRE
Oct-21-21 10:16AM	EDSA: Additional Favorable Mortality Reductions Identified in COVID-19 Trial Zacks Small Cap Research
Oct-19-21 09:32AM	Why Edesa Biotech Shares Are Trading Higher Today Benzinga +6.20%
08:00AM	Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study ACCESSWIRE
Oct-09-21 10:29AM	As Edesa Biotech, Inc. (NASDAQ:EDSA) gains 11%, insiders who bought last year may be wishing they had bet higher Simply Wall St.
Sep-22-21 04:46AM	50 Biggest Movers From Yesterday Benzinga
Sep-20-21 02:43PM	Why Edesa Biotech Shares Are Soaring Today Benzinga +102.72%
01:55PM	How To Play Edsa Biotech's Stock After 60% Surge Benzinga
12:37PM	Edesa Biotech Stock Is Rallying After COVID-19 Antibody Data: What You Need To Know Benzinga
11:11AM	EDSA: EB05 Reduces Risk of COVID Death by 68.5% in Critically Ill Patients Zacks Small Cap Research
08:00AM	Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients ACCESSWIRE
Sep-09-21 07:00AM	Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference ACCESSWIRE
Sep-01-21 10:30AM	EDSA: Awaiting End of Phase 2 Analysis of Phase 2/3 Study of EB05 in COVID19 Zacks Small Cap Research
Aug-26-21 01:01PM	Edesa Biotech Provides Update For COVID-19 Antibody Trial Benzinga +5.34%
07:30AM	Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule ACCESSWIRE
Aug-13-21 07:50AM	Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results ACCESSWIRE
Aug-05-21 02:00AM	iOnctura Strengthens Management With Appointment of Sean A. MacDonald as Chief Business Officer GlobeNewswire
Jul-13-21 08:10AM	Edesa Biotech Extends Dermatitis Study to Canada ACCESSWIRE
Jun-24-21 02:50AM	Here's Why We're Watching Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation Simply Wall St.
Jun-23-21 07:55AM	Edesa Biotech Team Expands Leadership Team with Key Manufacturing Appointment ACCESSWIRE
Jun-18-21 08:50AM	Edesa Biotech shares jump 14% premarket after early review of COVID treatment finds it should continue trial MarketWatch
07:45AM	Edesa Biotech Reports Favorable Review of COVID-19 Study ACCESSWIRE
Jun-08-21 08:00AM	Edesa Biotech to Attend BIO Digital 2021 ACCESSWIRE
Jun-04-21 06:52AM	EDSA: Positive Interim Efficacy Analysis for EB01 Phase 2b Trial in Allergic Contact Dermatitis Zacks Small Cap Research
Jun-03-21 08:47AM	Edesa Biotech's EB01 Shows Encouraging Interim Results In Dermatitis Trial Benzinga
07:30AM	Edesa Biotech Reports Positive Interim Results in Dermatitis Trial ACCESSWIRE
May-28-21 08:00AM	Edesa Biotech to Join Panel Discussion at Industry Event ACCESSWIRE
May-18-21 08:27AM	EDSA: Nearing Enrollment Completion for Phase 2 Portion of EB05 Trial in COVID-19 Zacks Small Cap Research
May-14-21 08:00AM	Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results ACCESSWIRE
Apr-22-21 08:00AM	Edesa Biotech to Host Key Opinion Leader Webinar on EB05 for the Treatment of Acute Respiratory Distress Syndrome ACCESSWIRE
Mar-26-21 11:14AM	Insider Buys Edesa Biotech Inc.'s Stock Benzinga
03:10AM	Who Has Been Buying Edesa Biotech, Inc. (NASDAQ:EDSA) Shares? Simply Wall St.
Mar-22-21 07:45AM	Edesa Biotech Expands Rights to Anti-Inflammatory Technology ACCESSWIRE
Mar-15-21 08:10AM	Edesa Biotech Reaches Enrollment Milestone in COVID Study ACCESSWIRE +6.43%
Mar-09-21 06:30AM	Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone ACCESSWIRE
Mar-02-21 04:10PM	Edesa Biotech Announces Closing of $10 Million Bought Deal Offering of Common Shares ACCESSWIRE
Feb-25-21 10:20PM	Edesa Biotech Increases Previously Announced Bought Deal Offering of Common Shares to $10.0 Million ACCESSWIRE
05:12PM	Edesa Biotech Announces $3.5 Million Bought Deal Offering of Common Shares ACCESSWIRE
Feb-17-21 05:07AM	EDSA: Secures CAD$14 Million for COVID-19 Trial of EB05 Zacks Small Cap Research +6.74%
Feb-16-21 07:30AM	Edesa Biotech Reports Fiscal First Quarter 2021 Results ACCESSWIRE
Feb-02-21 12:15PM	Edesa Biotech Receives C$14 million for COVID-19 Study ACCESSWIRE
Jan-26-21 07:30AM	Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy ACCESSWIRE +35.26%
Jan-20-21 07:45AM	Edesa Biotech to Join Panel Discussion at Government COVID-19 Event ACCESSWIRE +11.39%
Jan-11-21 07:30AM	Edesa Biotech Expands COVID-19 Clinical Study to Colombia ACCESSWIRE
Dec-30-20 08:00AM	Edesa Biotech Issues Letter to Shareholders ACCESSWIRE
Dec-10-20 05:36AM	EDSA: FIRST PATIENT ENROLLED IN COVID-19 TRIAL Zacks Small Cap Research +25.99%
Dec-08-20 01:18AM	We're Hopeful That Edesa Biotech (NASDAQ:EDSA) Will Use Its Cash Wisely Simply Wall St.
Dec-07-20 07:45AM	Edesa Biotech Reports Fiscal Year 2020 Results ACCESSWIRE
Nov-30-20 07:30AM	Edesa Biotech Enrolls First Patient in COVID-19 Study ACCESSWIRE
Nov-06-20 08:00AM	Edesa Biotech to Present at H.C. Wainwright & Co. 6th Annual Israel Conference ACCESSWIRE -5.45%
Nov-03-20 07:25AM	Edesa Biotech Achieves Enrollment Milestone in Dermatitis Study ACCESSWIRE
Oct-19-20 07:30AM	Edesa Biotech Receives Approval to Initiate COVID-19 Study in the U.S. ACCESSWIRE
Aug-31-20 05:00PM	LD Micro -- 360 Companies Set to Present this Week ACCESSWIRE +14.48%
Aug-21-20 04:02PM	EDSA: Set to Initiate Clinical Trial of EB05 in COVID-19 Patients Zacks Small Cap Research -8.56%
05:55AM	EDSA: Set to Initiate Clinical Trial of EB05 in COVID-19 Patients Zacks Small Cap Research
Aug-12-20 07:45AM	Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results ACCESSWIRE -16.75%
Jul-30-20 07:45AM	Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study ACCESSWIRE +81.73%
Jun-15-20 08:15AM	Edesa Biotech Receives Regulatory Approval to Initiate COVID-19 Study ACCESSWIRE +100.00%
May-27-20 07:20AM	EDSA: Interim Analysis of Phase 2b Trial of EB01 in second half of 2020 Zacks Small Cap Research
May-19-20 06:47AM	Companies Like Edesa Biotech (NASDAQ:EDSA) Can Be Considered Quite Risky Simply Wall St.
May-15-20 08:00AM	Edesa Biotech Reports Fiscal 2nd Quarter 2020 Results ACCESSWIRE
Apr-24-20 08:35AM	EDSA: Licenses Two Potential COVID-19 Treatments Zacks Small Cap Research
Apr-20-20 09:00AM	Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders ACCESSWIRE
Apr-02-20 10:33AM	EDSA: Initiating Coverage of Edesa Biotech, Inc.; Dermatology and GI Focused Drug Development Zacks Small Cap Research
Mar-12-20 07:30AM	Edesa Biotech to Develop Novel Treatment for Vitiligo in Collaboration with the National Research Council of Canada ACCESSWIRE -19.60%
Feb-13-20 04:10PM	Edesa Biotech Reports Fiscal 1st Quarter 2020 Results ACCESSWIRE
Jan-06-20 09:21AM	Edesa Biotech Announces $4.36 million Registered Direct Offering ACCESSWIRE -21.30%
Dec-12-19 04:30PM	Edesa Biotech Reports Financial Results for Short Period Fiscal Year ACCESSWIRE
Dec-03-19 07:30AM	Edesa Biotech Reports Positive Healthy Volunteer Data and Expands Phase 2b Dermatitis Study to Patients with Facial Lesions ACCESSWIRE
Nov-05-19 07:30AM	Edesa Biotech Announces Upcoming Conference Schedule ACCESSWIRE
Oct-21-19 07:30AM	Edesa Biotech Enrolls First Patient in Phase 2b Dermatitis Study ACCESSWIRE
Aug-29-19 08:30AM	Edesa Biotech to Present at H. C. Wainwright Global Investment Conference ACCESSWIRE +7.37%
Aug-14-19 04:05PM	Edesa Biotech Reports Quarterly Financial Results ACCESSWIRE
Jul-25-19 07:30AM	Edesa Biotech Completes Manufacturing for Upcoming Dermatitis Study ACCESSWIRE
Jun-20-19 12:12PM	Edesa Biotech (EDSA) Stock Rockets Higher on Dermatitis Study Approval InvestorPlace +74.94%
08:26AM	Edesa Biotech stock rockets 140% after FDA gives go-ahead to early-stage trial MarketWatch
07:30AM	Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study PR Newswire
07:30AM	Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study CNW Group

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brooks Michael J	President	Mar 25	Buy	5.19	3,500	18,165	13,241	Mar 26 11:44 AM
Nijhawan Pardeep	Chief Executive Officer	Mar 25	Buy	5.25	3,000	15,750	545,312	Mar 26 11:44 AM
Nijhawan Pardeep	Chief Executive Officer	Mar 24	Buy	5.16	5,000	25,800	542,312	Mar 25 02:43 PM
OAKES FRANK R.	Director	Feb 18	Sale	7.25	1,827	13,246	0	Feb 18 07:40 PM
OAKES FRANK R.	Director	Feb 18	Sale	7.25	6,165	44,696	0	Feb 18 07:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience